These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34877663)

  • 1. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
    Ailani J; Blumenfeld AM
    Headache; 2022 Jan; 62(1):106-108. PubMed ID: 34877663
    [No Abstract]   [Full Text] [Related]  

  • 2. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Moskatel LS; Graber-Naidich A; He Z; Zhang N
    Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study.
    Alpuente A; Gallardo VJ; Caronna E; Torres-Ferrús M; Pozo-Rosich P
    Eur J Neurol; 2021 Jul; 28(7):2378-2382. PubMed ID: 33730441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
    Drellia K; Kokoti L; Deligianni CI; Papadopoulos D; Mitsikostas DD
    Cephalalgia; 2021 Jun; 41(7):851-864. PubMed ID: 33567891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
    Scuteri D; Tonin P; Nicotera P; Vulnera M; Altieri GC; Tarsitano A; Bagetta G; Corasaniti MT
    Toxins (Basel); 2022 Aug; 14(8):. PubMed ID: 36006191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum Toxin in the Treatment of Headache.
    Becker WJ
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33348571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
    Pellesi L; Do TP; Ashina H; Ashina M; Burstein R
    Headache; 2020 Jun; 60(6):1056-1065. PubMed ID: 32437038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2022 Taiwan Guidelines for Preventive Treatment of Migraine.
    Wu JW; Yang CP;
    Acta Neurol Taiwan; 2022 Sep; 31(3)():164-202. PubMed ID: 36089629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.
    Cohen F; Armand C; Lipton RB; Vollbracht S
    Pain Med; 2021 Aug; 22(8):1857-1863. PubMed ID: 33693863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K; Vandenbussche N; Goadsby PJ
    Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine.
    Guerzoni S; Baraldi C; Pani L
    Neurol Sci; 2022 Sep; 43(9):5687-5695. PubMed ID: 35680766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis.
    Gaul C; Seidel K; Heuck A; Silaidos C; Mrosowsky T; Eberhardt A; Fritz B; Jacob C
    J Med Econ; 2023; 26(1):667-678. PubMed ID: 37126606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nummular headache responsive to anti-calcitonin gene-related peptide monoclonal antibodies in a patient with migraine.
    López-Bravo A; Oliveros-Cid A; Mínguez-Olaondo A; Cuadrado ML
    Headache; 2022 Sep; 62(8):1063-1066. PubMed ID: 36018002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galcanezumab for the prevention of migraine.
    Frerichs LM; Friedman DI
    Pain Manag; 2021 Mar; 11(2):101-112. PubMed ID: 33291980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
    Hong P; Wu X; Liu Y
    Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.